Therapeutic advances in vaccines最新文献_第2页

Intentions to receive a potentially available Lyme disease vaccine in an urban sample. 在城市样本中接受可能可用的莱姆病疫苗的意图。

Therapeutic advances in vaccines Pub Date : 2016-01-01 DOI: 10.1177/2051013616629881

Joshua Fogel, Martin Kusz

{"title":"Intentions to receive a potentially available Lyme disease vaccine in an urban sample.","authors":"Joshua Fogel, Martin Kusz","doi":"10.1177/2051013616629881","DOIUrl":"https://doi.org/10.1177/2051013616629881","url":null,"abstract":"Objectives: The only human Lyme disease vaccine of LYMErix was voluntarily removed from the market in the United States in 2002 for a number of reasons. A new human Lyme disease vaccine is currently being developed. We would like any future approved human Lyme disease vaccine to be of interest and marketable to consumers.Methods: We surveyed 714 participants to determine variables associated with intentions to receive a Lyme disease vaccine. Predictor variables included demographics, protection motivational theory, Lyme disease knowledge, Lyme disease preventive behaviors, beliefs and perceived health.Results: We found in multivariate linear regression analyses that Asian/Asian American race/ethnicity (p < 0.001), South Asian race/ethnicity (p = 0.01) and coping appraisal variables of response efficacy (p < 0.001) and self-efficacy (p < 0.001) were each significantly associated with increased intentions. The belief that vaccines are typically not safe was significantly associated with decreased intentions (p = 0.03).Conclusions: Asian/Asian American and South Asian race/ethnicities have a strong interest in receiving a Lyme disease vaccine. Although pharmaceutical companies may benefit by advertising a Lyme disease vaccine to Asian/Asian Americans and South Asians, marketers need to address and use approaches to interest those from other race/ethnicities. Also, marketers need to address the erroneous belief that vaccines are typically not safe in order to interest those with such beliefs to use a Lyme disease vaccine.","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"4 1-2","pages":"3-14"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013616629881","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34383610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Efficacy of varicella (VZV) vaccination: an update for the clinician. 水痘(VZV)疫苗接种的有效性:临床医生的更新。

Therapeutic advances in vaccines Pub Date : 2016-01-01 DOI: 10.1177/2051013616655980

Lili Wang, Lucy Zhu, Hua Zhu

{"title":"Efficacy of varicella (VZV) vaccination: an update for the clinician.","authors":"Lili Wang, Lucy Zhu, Hua Zhu","doi":"10.1177/2051013616655980","DOIUrl":"https://doi.org/10.1177/2051013616655980","url":null,"abstract":"Varicella-zoster virus (VZV) infection causes two distinct clinical conditions. Primary varicella infection results in chickenpox, a contagious rash illness typically seen among children. VZV can reactivate years after the initial infection to cause herpes zoster (HZ) and lead to post-herpetic neuralgia, a common complication resulting in persistent pain that may last for years after the zoster rash resolves. A person's risk of having longer lasting and more severe pain associated with HZ increases with age. Since the introduction of VZV vaccines, the rates of infection, hospitalizations, and mortality have declined. In this review, we discuss in detail current VZV vaccines available for the prevention of VZV and HZ infections. Varilrix (GSK Biologicals, UK), Varivax (Merck, USA) and the combined measles, mumps, rubella, and varicella (MMRV) vaccine contain the live attenuated Oka strain of VZV for routine varicella vaccination. While Zostavax is the only HZ vaccine currently approved for use in the United States and the European Union [EMEA, 2011], a subunit vaccine candidate called HZ/su has recently shown improved efficacy for zoster prevention in two clinical trial phase III studies. VariZIG, a post-exposure prophylactic, uses zoster immune globulin to prevent VZV infection in those who have recently been in contact with VZV but lack evidence of varicella immunity and are contraindicated to receive the varicella vaccine. Further, we discuss the skin tropic and neurotropic factor VZV ORF7 gene and its involvement in varicella infection, reactivation and latency in ganglia. Ultimately, these studies can contribute to the development of a neuroattenuated vaccine candidate against varicella or a vector for delivery of other virus antigens. ","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"4 1-2","pages":"20-31"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013616655980","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34383612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42

Erratum. 勘误表。

Therapeutic advances in vaccines Pub Date : 2016-01-01 DOI: 10.1177/2051013616634209

引用次数: 0

Cholera toxin B induced activation of murine macrophages exposed to a fixed bacterial immunogen 霍乱毒素B诱导暴露于固定细菌免疫原的小鼠巨噬细胞活化

Therapeutic advances in vaccines Pub Date : 2015-09-01 DOI: 10.1177/2051013615613473

Kari Wiedinger, Heather Romlein, C. Bitsaktsis

{"title":"Cholera toxin B induced activation of murine macrophages exposed to a fixed bacterial immunogen","authors":"Kari Wiedinger, Heather Romlein, C. Bitsaktsis","doi":"10.1177/2051013615613473","DOIUrl":"https://doi.org/10.1177/2051013615613473","url":null,"abstract":"Objectives: Previous studies have demonstrated that intranasal administration of inactivated (fixed) Francisella tularensis (iFt) live vaccine strain (LVS) in conjunction with the mucosal adjuvant, cholera toxin B (CTB), provides full protection against subsequent lethal challenge with Ft LVS and partial protection against the more virulent Ft SchuS4 strain. Understanding the mechanisms of CTB-induced immune stimulation that confer protection against Ft will be valuable to the development of an effective vaccine against this highly virulent fatal pathogen. In this study, an in vitro system was utilized to further elucidate the immunologic adjuvant effect of CTB when administered with the fixed bacterial immunogen iFt. Methods: The murine macrophage cell line (RAW264.7) was treated with combinations of iFt and CTB. The treated RAW264.7 cells and their supernatants were collected and assessed for cell surface marker expression and cytokine secretion. In addition, the ability of RAW264.7 cells to present bacterial antigens (iFt or LVS) to an Ft-specific T-cell hybridoma cell line, following exposure to CTB, was analyzed. Results: We found that RAW264.7 cells responded to treatment with iFt + CTB by an increased secretion of the proinflammatory cytokines interleukin 6 and tumor necrosis factor α and upregulation of the surface expression of toll-like receptor 4 and the costimulatory molecules CD80 and CD86. Furthermore, the experimental vaccine treatment iFt + CTB enhanced the ability of macrophages to present iFt antigens to an FT-specific T-cell hybridoma cell line, although they failed to do so with LVS. Conclusion: The adjuvant CTB administered in conjunction with iFt showed evidence of enhancing an antigen-specific proinflammatory response in vitro. These observations allow us to define, in part, the mechanisms of immune activation conferred by mucosal administration of iFt + CTB against lethal F. tularensis challenge.","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"3 1","pages":"155 - 163"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013615613473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65465855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Plant-based vaccines for animals and humans: recent advances in technology and clinical trials 动物和人用植物疫苗:技术和临床试验的最新进展

Therapeutic advances in vaccines Pub Date : 2015-09-01 DOI: 10.1177/2051013615613272

N. Takeyama, H. Kiyono, Y. Yuki

引用次数: 122

Clinical development of Ebola vaccines. 埃博拉疫苗的临床开发。

Therapeutic advances in vaccines Pub Date : 2015-09-01 DOI: 10.1177/2051013615611017

Saranya Sridhar

引用次数: 0

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. 欧洲带状疱疹流行病学、管理、疾病和经济负担：多学科视角。

Therapeutic advances in vaccines Pub Date : 2015-07-01 DOI: 10.1177/2051013615599151

Robert W Johnson, Marie-José Alvarez-Pasquin, Marc Bijl, Elisabetta Franco, Jacques Gaillat, João G Clara, Marc Labetoulle, Jean-Pierre Michel, Luigi Naldi, Luis S Sanmarti, Thomas Weinke

{"title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.","authors":"Robert W Johnson, Marie-José Alvarez-Pasquin, Marc Bijl, Elisabetta Franco, Jacques Gaillat, João G Clara, Marc Labetoulle, Jean-Pierre Michel, Luigi Naldi, Luis S Sanmarti, Thomas Weinke","doi":"10.1177/2051013615599151","DOIUrl":"10.1177/2051013615599151","url":null,"abstract":"Herpes zoster (HZ) is primarily a disease of nerve tissue but the acute and longer-term manifestations require multidisciplinary knowledge and involvement in their management. Complications may be dermatological (e.g. secondary bacterial infection), neurological (e.g. long-term pain, segmental paresis, stroke), ophthalmological (e.g. keratitis, iridocyclitis, secondary glaucoma) or visceral (e.g. pneumonia, hepatitis). The age-related increased incidence of HZ and its complications is thought to be a result of the decline in cell-mediated immunity (immunosenescence), higher incidence of comorbidities with age and social-environmental changes. Individuals who are immunocompromised as a result of disease or therapy are also at increased risk, independent of age. HZ and its complications (particularly postherpetic neuralgia) create a significant burden for the patient, carers, healthcare systems and employers. Prevention and treatment of HZ complications remain a therapeutic challenge despite recent advances. This is an overview of the multidisciplinary implications and management of HZ in which the potential contribution of vaccination to reducing the incidence HZ and its complications are also discussed. ","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"3 4","pages":"109-20"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591524/pdf/10.1177_2051013615599151.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34269030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Flublok预防成人季节性流感的安全性、有效性和免疫原性。

Therapeutic advances in vaccines Pub Date : 2015-07-01 DOI: 10.1177/2051013615595595

Manon M J Cox, Ruvim Izikson, Penny Post, Lisa Dunkle

{"title":"Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.","authors":"Manon M J Cox, Ruvim Izikson, Penny Post, Lisa Dunkle","doi":"10.1177/2051013615595595","DOIUrl":"https://doi.org/10.1177/2051013615595595","url":null,"abstract":"Flublok is the first recombinant hemagglutinin (HA) vaccine licensed by the US Food and Drugs Administration for the prevention of influenza in adults aged 18 and older. The HA proteins produced in insect cell culture using the baculovirus expression system technology are exact analogues of wild type circulating influenza virus HAs. The universal HA manufacturing process that has been successfully scaled to the 21,000L contributes to rapid delivery of a substantial number of doses. This review discusses the immunogenicity, efficacy and safety data from five pivotal clinical studies used to support licensure of trivalent Flublok for adults 18 years of age and older in the United States. The trial data demonstrate that the higher antigen content in Flublok results in improved immunogenicity. Data further suggest improved efficacy and a slightly lower local reactogenicity compared with standard inactivated influenza vaccine, despite the presence of more antigen (statistically significant). Flublok influenza vaccine can include HAs designed to mimic 'drift' in influenza viruses as the process of predicting antigenic drift advances and, at a minimum, could address late appearing influenza viruses. The implementation of the latter will require support from regulatory authorities. ","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"3 4","pages":"97-108"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013615595595","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34269029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 83

Group B Streptococcus vaccine: state of the art. B群链球菌疫苗:最先进的。

Therapeutic advances in vaccines Pub Date : 2015-05-01 DOI: 10.1177/2051013615579869

Annalisa Nuccitelli, C Daniela Rinaudo, Domenico Maione

{"title":"Group B Streptococcus vaccine: state of the art.","authors":"Annalisa Nuccitelli, C Daniela Rinaudo, Domenico Maione","doi":"10.1177/2051013615579869","DOIUrl":"https://doi.org/10.1177/2051013615579869","url":null,"abstract":"Group B Streptococcus (GBS) is cause of neonatal invasive diseases as well as of severe infections in the elderly and immune-compromised patients. Despite significant advances in the prevention and treatment of neonatal disease, sepsis and meningitis caused by GBS still represent a significant public health care concern globally and additional prevention and therapeutic strategies against infection are highly desirable. The introduction of national recommended guidelines in several countries to screen pregnant women for GBS carriage and the use of antibiotics during delivery significantly reduced disease occurring within the first hours of life (early-onset disease), but it has had no effect on the late-onset diseases occurring after the first week and is not feasible in most countries. Availability of an effective vaccine against GBS would provide an effective means of controlling GBS disease. This review provides an overview of the burden of invasive disease caused by GBS in infants and adults, and highlights the strategies for the development of an effective vaccine against GBS infections. ","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"3 3","pages":"76-90"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013615579869","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33932858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 97

Recent advances in immunotherapy and vaccine development for peanut allergy. 花生过敏免疫治疗及疫苗研究进展。

Therapeutic advances in vaccines Pub Date : 2015-05-01 DOI: 10.1177/2051013615591739

Katherine Anagnostou

{"title":"Recent advances in immunotherapy and vaccine development for peanut allergy.","authors":"Katherine Anagnostou","doi":"10.1177/2051013615591739","DOIUrl":"https://doi.org/10.1177/2051013615591739","url":null,"abstract":"Peanut allergy is a common problem and can be the cause of severe, life-threatening allergic reactions. It rarely resolves, with the majority of patients carrying the disease onto adulthood. Peanut allergy poses a significant burden on the quality of life of sufferers and their families, which results mainly from the fear of accidental peanut ingestion, but is also due to dietary and social restrictions. Current standard management involves avoidance, patient education and provision of emergency medication, for use in allergic reactions, when they occur. Efforts have been made to develop a vaccine for peanut allergy. Recent developments have also highlighted the use of immunotherapy, which has shown promise as an active form of treatment and may present a disease-modifying therapy for peanut allergy. So far, results, especially from oral immunotherapy studies, have shown good efficacy in achieving desensitization to peanut with a good safety profile. However, the capacity to induce long-term tolerance has not been demonstrated conclusively yet and larger, phase III studies are required to further investigate safety and efficacy of this intervention. Peanut immunotherapy is not currently recommended for routine clinical use or outside specialist allergy units. ","PeriodicalId":90371,"journal":{"name":"Therapeutic advances in vaccines","volume":"3 3","pages":"55-65"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013615591739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33932856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12